Citius Oncology Inc (CTOR)
1.03
-0.03
(-2.83%)
USD |
NASDAQ |
Nov 18, 12:43
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 73.38M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -- |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
URL | N/A |
Investor Relations URL | https://www.citiusonc.com/overview/default.aspx |
HQ State/Province | New York |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Nov. 29, 2024 (est.) |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
URL | N/A |
Investor Relations URL | https://www.citiusonc.com/overview/default.aspx |
HQ State/Province | New York |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Nov. 29, 2024 (est.) |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |